AU2003206738C1 - Pharmaceutical compositions comprising valsartan and NEP inhibitors - Google Patents

Pharmaceutical compositions comprising valsartan and NEP inhibitors Download PDF

Info

Publication number
AU2003206738C1
AU2003206738C1 AU2003206738A AU2003206738A AU2003206738C1 AU 2003206738 C1 AU2003206738 C1 AU 2003206738C1 AU 2003206738 A AU2003206738 A AU 2003206738A AU 2003206738 A AU2003206738 A AU 2003206738A AU 2003206738 C1 AU2003206738 C1 AU 2003206738C1
Authority
AU
Australia
Prior art keywords
diabetic
disease
renal
pharmaceutically acceptable
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2003206738A
Other languages
English (en)
Other versions
AU2003206738B2 (en
AU2003206738A1 (en
Inventor
Gary Michael Ksander
Randy Lee Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003206738(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003206738A1 publication Critical patent/AU2003206738A1/en
Priority to AU2006202999A priority Critical patent/AU2006202999A1/en
Publication of AU2003206738B2 publication Critical patent/AU2003206738B2/en
Application granted granted Critical
Publication of AU2003206738C1 publication Critical patent/AU2003206738C1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003206738A 2002-01-17 2003-01-16 Pharmaceutical compositions comprising valsartan and NEP inhibitors Active 2028-01-16 AU2003206738C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006202999A AU2006202999A1 (en) 2002-01-17 2006-07-13 Pharmaceutical compositions comprising valsartan and NEP inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34966002P 2002-01-17 2002-01-17
US60/349,660 2002-01-17
PCT/EP2003/000415 WO2003059345A1 (en) 2002-01-17 2003-01-16 Pharmaceutical compositions comprising valsartan and nep inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006202999A Division AU2006202999A1 (en) 2002-01-17 2006-07-13 Pharmaceutical compositions comprising valsartan and NEP inhibitors

Publications (3)

Publication Number Publication Date
AU2003206738A1 AU2003206738A1 (en) 2003-07-30
AU2003206738B2 AU2003206738B2 (en) 2006-12-21
AU2003206738C1 true AU2003206738C1 (en) 2020-01-30

Family

ID=23373410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003206738A Active 2028-01-16 AU2003206738C1 (en) 2002-01-17 2003-01-16 Pharmaceutical compositions comprising valsartan and NEP inhibitors

Country Status (29)

Country Link
EP (1) EP1467728B1 (enIt.pdf)
JP (2) JP4820056B2 (enIt.pdf)
KR (2) KR100984939B1 (enIt.pdf)
CN (2) CN102091330B (enIt.pdf)
AT (1) ATE370732T1 (enIt.pdf)
AU (1) AU2003206738C1 (enIt.pdf)
BE (1) BE2016C025I2 (enIt.pdf)
BR (2) BRPI0306907B8 (enIt.pdf)
CA (1) CA2472399C (enIt.pdf)
CO (1) CO5600999A2 (enIt.pdf)
CY (2) CY1106959T1 (enIt.pdf)
DE (1) DE60315795T2 (enIt.pdf)
DK (1) DK1467728T3 (enIt.pdf)
EC (1) ECSP045190A (enIt.pdf)
ES (1) ES2290429T3 (enIt.pdf)
FR (1) FR16C0019I2 (enIt.pdf)
HU (1) HUS1600024I1 (enIt.pdf)
IL (2) IL162661A0 (enIt.pdf)
LU (1) LU93074I2 (enIt.pdf)
MX (1) MXPA04006917A (enIt.pdf)
NL (1) NL300811I2 (enIt.pdf)
NO (2) NO333191B1 (enIt.pdf)
NZ (1) NZ533968A (enIt.pdf)
PL (1) PL212318B1 (enIt.pdf)
PT (1) PT1467728E (enIt.pdf)
RU (1) RU2334513C3 (enIt.pdf)
SI (1) SI1467728T1 (enIt.pdf)
WO (1) WO2003059345A1 (enIt.pdf)
ZA (1) ZA200405117B (enIt.pdf)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006000564A1 (en) * 2004-06-23 2006-01-05 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
US20080102120A1 (en) 2004-12-24 2008-05-01 Miha Vrbinc Solid Pharmaceutical Composition Comprising Valsartan
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) * 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
SI2121578T1 (sl) 2007-01-12 2016-12-30 Novartis Ag Postopek za pripravo 5-bifenil-4-amino-2-metil pentanojske kisline
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
SI3067043T1 (sl) 2007-11-06 2023-04-28 Novartis Ag Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
CN101774941A (zh) 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
KR101442897B1 (ko) 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
CN102448928B (zh) 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8835668B2 (en) 2010-08-23 2014-09-16 Novartis Ag Process for the preparation of intermediates for the manufacture of NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CN108685889A (zh) * 2012-08-24 2018-10-23 诺华股份有限公司 用于治疗特征为心房增大或重构的疾病的nep抑制剂
CA2900226A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
DK2956464T3 (en) 2013-02-14 2018-07-16 Novartis Ag Substituted bisphenyl-butane phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
EP3038653A1 (en) 2013-08-26 2016-07-06 Novartis AG New use
PT3626270T (pt) 2013-08-26 2024-01-11 Novartis Ag Tratamento de doenças cardiovasculares
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (en) * 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
HUE046278T2 (hu) 2014-11-14 2020-02-28 Zentiva Ks Módszer AHU-377 gyógyszerészetben alkalmazható formáinak elõállítására, izolálására és tisztítására
WO2016086798A1 (zh) * 2014-12-03 2016-06-09 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
US9957240B2 (en) * 2014-12-08 2018-05-01 Crystal Pharmatech Co., Ltd Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
CN106138069A (zh) * 2015-04-21 2016-11-23 刘春丽 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
WO2016193883A1 (en) 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
WO2017037577A1 (en) 2015-08-28 2017-03-09 Novartis Ag New use
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN105348209B (zh) * 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
MX2018007129A (es) 2015-12-11 2018-11-09 Zentiva Ks Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
US10722471B2 (en) 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
AU2017215530B2 (en) 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
EP3524250A4 (en) 2016-10-08 2020-05-20 Wuhan LL Science And Technology Development Co., Ltd. PHARMACEUTICAL COMPOSITION
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110237071B (zh) 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
WO2021158084A1 (ko) * 2020-02-07 2021-08-12 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013564A1 (en) * 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
JP2003533440A (ja) * 2000-04-03 2003-11-11 ブリストル−マイヤーズ スクイブ カンパニー 隔離心収縮期高血圧症を処置するバソペプチダーゼ抑制剤
NZ540748A (en) * 2000-06-22 2007-04-27 Novartis Ag An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1
CN1216873C (zh) * 2000-07-19 2005-08-31 诺瓦提斯公司 缬沙坦的盐
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
References cited in WO 03/059345 *

Also Published As

Publication number Publication date
KR100984939B1 (ko) 2010-10-01
CA2472399C (en) 2012-02-21
CN1615134A (zh) 2005-05-11
FR16C0019I2 (fr) 2017-12-08
AU2003206738B2 (en) 2006-12-21
FR16C0019I1 (enIt.pdf) 2016-06-24
NL300811I2 (enIt.pdf) 2016-07-27
BR122018015003B1 (pt) 2018-11-21
MXPA04006917A (es) 2004-12-06
JP4820056B2 (ja) 2011-11-24
JP2011207898A (ja) 2011-10-20
IL162661A (en) 2010-11-30
NO2016009I1 (no) 2016-05-18
NO333191B1 (no) 2013-03-25
EP1467728B1 (en) 2007-08-22
DK1467728T3 (da) 2007-12-27
RU2334513C2 (ru) 2008-09-27
CY2016013I2 (el) 2016-10-05
ATE370732T1 (de) 2007-09-15
BRPI0306907B1 (pt) 2018-10-30
BRPI0306907B8 (pt) 2021-05-25
NO2016009I2 (no) 2016-05-18
KR20100057704A (ko) 2010-05-31
CO5600999A2 (es) 2006-01-31
ES2290429T3 (es) 2008-02-16
DE60315795T2 (de) 2008-06-05
HUS1600024I1 (hu) 2016-06-28
ZA200405117B (en) 2005-08-31
NZ533968A (en) 2006-10-27
SI1467728T1 (sl) 2008-02-29
BR0306907A (pt) 2004-12-21
ECSP045190A (es) 2004-08-27
PL212318B1 (pl) 2012-09-28
CY2016013I1 (el) 2016-10-05
DE60315795D1 (de) 2007-10-04
BE2016C025I2 (enIt.pdf) 2022-05-17
PL369773A1 (en) 2005-05-02
EP1467728A1 (en) 2004-10-20
BR122018015003B8 (pt) 2021-07-27
AU2003206738A1 (en) 2003-07-30
KR20040078127A (ko) 2004-09-08
LU93074I2 (fr) 2016-07-18
WO2003059345A1 (en) 2003-07-24
CA2472399A1 (en) 2003-07-24
CY1106959T1 (el) 2012-01-25
RU2334513C3 (ru) 2017-10-24
CN102091330B (zh) 2015-04-08
CN102091330A (zh) 2011-06-15
NO20043380L (no) 2004-10-07
RU2004125178A (ru) 2005-06-10
PT1467728E (pt) 2007-11-14
JP2005514441A (ja) 2005-05-19
IL162661A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
HUS1600024I1 (hu) Valsartant és NEP inhibitorokat tartalmazó gyógyszerkészítmények
WO2007106708A3 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
NL300800I2 (enIt.pdf)
EP1507558B8 (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
BR0317384A (pt) Combinações de valsartan com inibidores de cox-2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ENTRESTO 97/103 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; ENTRESTO 24/26 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; NOVARTIS SACUBITRIL/VALSARTAN 97/103 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; NOVARTIS SACUBITRIL/VALSARTAN 24/26 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; ENTRESTO 49/51 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; NOVARTIS SACUBITRIL/VALSARTAN 49/51 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)

Filing date: 20160120

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: ENTRESTO 97/103 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; ENTRESTO 24/26 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; NOVARTIS SACUBITRIL/VALSARTAN 97/103 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; NOVARTIS SACUBITRIL/VALSARTAN 24/26 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; ENTRESTO 49/51 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX) ; NOVARTIS SACUBITRIL/VALSARTAN 49/51 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)

Filing date: 20160120

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ENTRESTO 97/103 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)ENTRESTO 24/26 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)NOVARTIS SACUBITRIL/VALSARTAN 97/103 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)NOVARTIS SACUBITRIL/VALSARTAN 24/26 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)ENTRESTO 49/51 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)NOVARTIS SACUBITRIL/VALSARTAN 49/51 SACUBITRIL/VALSARTAN (COMBINED AS A SODIUM SALT HYDRATE COMPLEX)

Filing date: 20160120

Extension date: 20280116

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 OCT 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 14 OCT 2019

GD Licence registered

Name of requester: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED